SG11202003671VA - Non-neuronal snare-cleaving botulinum neurotoxins - Google Patents
Non-neuronal snare-cleaving botulinum neurotoxinsInfo
- Publication number
- SG11202003671VA SG11202003671VA SG11202003671VA SG11202003671VA SG11202003671VA SG 11202003671V A SG11202003671V A SG 11202003671VA SG 11202003671V A SG11202003671V A SG 11202003671VA SG 11202003671V A SG11202003671V A SG 11202003671VA SG 11202003671V A SG11202003671V A SG 11202003671VA
- Authority
- SG
- Singapore
- Prior art keywords
- cleaving
- botulinum neurotoxins
- neuronal snare
- snare
- neuronal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153941 | 2018-01-29 | ||
| PCT/EP2019/052146 WO2019145577A1 (en) | 2018-01-29 | 2019-01-29 | Non-neuronal snare-cleaving botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003671VA true SG11202003671VA (en) | 2020-08-28 |
Family
ID=61231041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003671VA SG11202003671VA (en) | 2018-01-29 | 2019-01-29 | Non-neuronal snare-cleaving botulinum neurotoxins |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11634460B2 (en) |
| EP (1) | EP3746463A1 (en) |
| JP (2) | JP7229247B2 (en) |
| KR (1) | KR20200115479A (en) |
| CN (1) | CN111406066A (en) |
| AU (2) | AU2019211190B2 (en) |
| BR (1) | BR112020006827A2 (en) |
| CA (2) | CA3083083A1 (en) |
| EA (1) | EA202091296A1 (en) |
| MX (1) | MX2020007596A (en) |
| SG (1) | SG11202003671VA (en) |
| TW (1) | TWI822723B (en) |
| WO (1) | WO2019145577A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| CA3154363C (en) | 2019-10-18 | 2024-03-05 | Penland Foundation | Use of a botulinum toxin for treating autism and/or tolerance to narcotics |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| US20230332126A1 (en) * | 2020-08-26 | 2023-10-19 | The Regents Of The University Of California | Botulinum Neurotoxin Proteins and Methods to Engineer and Generate Same |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| AU2021438810A1 (en) | 2021-03-30 | 2023-09-21 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| BR112023020057A2 (en) | 2021-03-30 | 2024-03-12 | Ipsen Biopharm Ltd | TREATMENT OF PAIN AND INFLAMMATORY DISORDERS |
| WO2023287728A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| WO2023287729A1 (en) * | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
| CA3234608A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| WO2024069191A1 (en) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US7491799B2 (en) | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
| US20020127247A1 (en) | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7223577B2 (en) | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
| GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| EP1834962A1 (en) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGylated mtutated Clostridium botulinum toxin |
| EP2038299A2 (en) | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| CA2658260A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| US20110171191A1 (en) | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| JP5799397B2 (en) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | Cancer suppression |
| GB0815264D0 (en) | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
| US8492109B2 (en) * | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| EP2419128B1 (en) | 2009-04-14 | 2018-06-06 | Medical College of Wisconsin, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) * | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| AU2015301737B2 (en) * | 2014-08-12 | 2021-01-28 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
| AU2016310521A1 (en) | 2015-08-27 | 2018-03-01 | Massachusetts Institute Of Technology | Compositions and methods for treatment of pain |
-
2019
- 2019-01-29 CA CA3083083A patent/CA3083083A1/en active Pending
- 2019-01-29 TW TW108102571A patent/TWI822723B/en active
- 2019-01-29 CA CA3220194A patent/CA3220194A1/en active Pending
- 2019-01-29 AU AU2019211190A patent/AU2019211190B2/en active Active
- 2019-01-29 KR KR1020207018521A patent/KR20200115479A/en not_active Application Discontinuation
- 2019-01-29 WO PCT/EP2019/052146 patent/WO2019145577A1/en active Application Filing
- 2019-01-29 CN CN201980006010.7A patent/CN111406066A/en active Pending
- 2019-01-29 EA EA202091296A patent/EA202091296A1/en unknown
- 2019-01-29 BR BR112020006827-6A patent/BR112020006827A2/en unknown
- 2019-01-29 JP JP2020530630A patent/JP7229247B2/en active Active
- 2019-01-29 US US16/754,844 patent/US11634460B2/en active Active
- 2019-01-29 SG SG11202003671VA patent/SG11202003671VA/en unknown
- 2019-01-29 MX MX2020007596A patent/MX2020007596A/en unknown
- 2019-01-29 EP EP19701378.2A patent/EP3746463A1/en active Pending
-
2021
- 2021-10-08 AU AU2021245226A patent/AU2021245226B2/en active Active
-
2023
- 2023-02-14 JP JP2023020549A patent/JP2023058652A/en active Pending
- 2023-03-15 US US18/184,627 patent/US20230312661A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201940698A (en) | 2019-10-16 |
| AU2021245226A1 (en) | 2021-11-04 |
| EA202091296A1 (en) | 2020-10-23 |
| MX2020007596A (en) | 2020-09-03 |
| BR112020006827A2 (en) | 2020-10-06 |
| EP3746463A1 (en) | 2020-12-09 |
| US20200239528A1 (en) | 2020-07-30 |
| US20230312661A1 (en) | 2023-10-05 |
| CN111406066A (en) | 2020-07-10 |
| CA3083083A1 (en) | 2019-08-01 |
| TWI822723B (en) | 2023-11-21 |
| CA3220194A1 (en) | 2019-08-01 |
| AU2019211190B2 (en) | 2021-07-08 |
| WO2019145577A1 (en) | 2019-08-01 |
| AU2019211190A1 (en) | 2020-04-23 |
| AU2021245226B2 (en) | 2024-02-29 |
| JP7229247B2 (en) | 2023-02-27 |
| KR20200115479A (en) | 2020-10-07 |
| JP2023058652A (en) | 2023-04-25 |
| US11634460B2 (en) | 2023-04-25 |
| JP2021514176A (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202003671VA (en) | Non-neuronal snare-cleaving botulinum neurotoxins | |
| IL263058A (en) | Engineered botulinum neurotoxins | |
| ZA201900341B (en) | A novel botulinum neurotoxin and its derivatives | |
| IL262575B (en) | Chimeric neurotoxins | |
| HK1249119A1 (en) | Engineered botulinum neurotoxin | |
| HK1245292A1 (en) | Cationic neurotoxins | |
| IL253429B (en) | Botulinum toxin prefilled container | |
| IL262612A (en) | Botulinum toxin prefilled syringe system | |
| GB201621111D0 (en) | Neurotoxins | |
| SG11201607400VA (en) | Manufacture of recombinant clostridium botulinum neurotoxins | |
| EP3570816C0 (en) | Stable liquid composition comprising botulinum toxin | |
| EP3600221A4 (en) | Botulinum neurotoxins for use in therapy | |
| EP3615669A4 (en) | Botulinum neurotoxins production methods | |
| IL276930A (en) | Botulinum neurotoxin biohybrid | |
| PL3717774T3 (en) | Injection system | |
| EP3600385A4 (en) | Botulinum neurotoxins for treating traumatic injuries | |
| GB201719557D0 (en) | Polypeptide | |
| SG11202105592XA (en) | Botulinum toxin-stabilizing liquid composition | |
| EP3612154A4 (en) | Botulinum neurotoxins for treating hyperhidrosis | |
| AU2024202302A1 (en) | Chimeric neurotoxins | |
| GB201816653D0 (en) | Contaminant clostridial neurotoxins | |
| GB201917265D0 (en) | Bonded neurotoxins | |
| DK3468989T3 (en) | Peptider til at inhibere trypsin | |
| GB201708471D0 (en) | Polypeptide | |
| GB201604511D0 (en) | Antibacterial peptides |